Inactive Instrument

Research Alliance Corp. II Stock

Equities

RACB

US7608731094

Investment Holding Companies

Dynamic Chart
Research Alliance Corp. II(NasdaqCM:RACB) dropped from NASDAQ Composite Index CI
Research Alliance Corp. II Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Research Alliance Corp. II Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Research Alliance Corp. II Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Research Alliance Corp. II Announces Board Changes CI
Research Alliance Corp. II Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Research Alliance Corp. II Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Certain Class B Common Stock of Research Alliance Corp. II are subject to a Lock-Up Agreement Ending on 14-SEP-2021. CI
Research Alliance Corp. Ii Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Research Alliance Corp. Ii Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Research Alliance Corp. II announced that it has received $4.99 million in funding from Research Alliance Holdings II LLC CI
Research Alliance Corp. II(NasdaqCM:RACB) added to NASDAQ Composite Index CI
Research Alliance Corp. II has completed an IPO in the amount of $130 million. CI
Research Alliance Corp. II has filed an IPO in the amount of $130 million. CI
Research Alliance Corp. II announced that it expects to receive $4.6 million in funding from Research Alliance Holdings II LLC CI
More news
Managers TitleAgeSince
Founder 35 20-07-16
Chief Executive Officer 47 20-07-16
Director of Finance/CFO - 20-07-16
Members of the board TitleAgeSince
Director/Board Member 70 21-02-28
Chief Executive Officer 47 20-07-16
Director/Board Member 47 21-01-31
More insiders
Research Alliance Corp. II is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It has not selected any specific business combination target and has not engaged in any substantive discussions, directly or indirectly, with any business combination target. The Company intend to focus on the healthcare industry, with an emphasis on the biotechnology sector. The Company neither engages in any business operations nor generates any revenues.
More about the company